I-Orforglipron iyinoveli yohlobo lwesifo sikashukela sohlobo 2 kanye nomuthi wokwelashwa wokuncipha kwesisindo esakhiwayo futhi kulindeleke ukuthi ibe ngenye indlela yomlomo kunemithi ejovwayo. Ingowomndeni wama-agonist we-glucagon-like peptide-1 (GLP-1) futhi ifana ne-Wegovy (Semaglutide) evame ukusetshenziswa kanye ne-Mounjaro (Tirzepatide). Inemisebenzi yokulawula ushukela egazini, ukucindezela ukudla kanye nokuthuthukisa ukusutha, ngaleyo ndlela usize ukulawula isisindo namazinga kashukela egazini.
Ngokungafani nezidakamizwa eziningi ze-GLP-1, inzuzo eyingqayizivele ye-Orforglipron ilele kufomu yayo yethebhulethi yomlomo yansuku zonke esikhundleni sokulawulwa komjovo wamasonto onke noma wansuku zonke. Le ndlela yokuphatha ithuthukise kakhulu ukuthobela kweziguli kanye nokuba lula ukuyisebenzisa, okumelela inqubekelaphambili ebalulekile kulabo abangawuthandi umjovo noma abangawuthandi umjovo.
Ezivivinyweni zomtholampilo, i-Orforglipron ibonise imiphumela emihle kakhulu yokuncipha kwesisindo. Idatha ibonisa ukuthi ababambiqhaza abathatha i-Orforglipron nsuku zonke amasonto angu-26 alandelanayo bathole ukwehla kwesisindo esimaphakathi kusuka ku-8% kuya ku-12%, okubonisa ukusebenza kahle kwayo okubalulekile ekulawuleni isisindo. Le miphumela yenze i-Orforglipron yaba ithemba elisha lokwelashwa okuzayo kwesifo sikashukela sohlobo 2 nokukhuluphala, futhi ikhombisa ukuthambekela okubalulekile emkhakheni wezidakamizwa ze-GLP-1, osuka ekubeni umjovo uye kumafomu omthamo womlomo.
Isikhathi sokuthumela: Jul-07-2025